XBiotech (NASDAQ:XBIT) Stock Price Crosses Above Fifty Day Moving Average of $7.66

XBiotech Inc. (NASDAQ:XBIT)’s stock price passed above its fifty day moving average during trading on Friday . The stock has a fifty day moving average of $7.66 and traded as high as $8.73. XBiotech shares last traded at $8.49, with a volume of 45,313 shares.

Analyst Ratings Changes

Separately, StockNews.com initiated coverage on shares of XBiotech in a research report on Thursday, February 15th. They set a “sell” rating for the company.

XBiotech Stock Up 5.9 %

The business has a 50 day moving average price of $7.66 and a 200 day moving average price of $5.56.

XBiotech (NASDAQ:XBIT) last announced its quarterly earnings results on Friday, March 15th. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter.

Institutional Trading of XBiotech

A hedge fund recently bought a new stake in XBiotech stock. National Bank of Canada FI bought a new position in shares of XBiotech Inc. (NASDAQ:XBIT) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 24,347 shares of the biopharmaceutical company’s stock, valued at approximately $103,000. National Bank of Canada FI owned approximately 0.08% of XBiotech as of its most recent SEC filing. Hedge funds and other institutional investors own 55.70% of the company’s stock.

XBiotech Company Profile

XBiotech Inc, a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation.